Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series.

Montanelli G, Beretta L, Santaniello A, Scorza R.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):135-9. Epub 2012 Dec 13.

PMID:
23295023
[PubMed - indexed for MEDLINE]
2.

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

Steen VD, Medsger TA Jr.

Arthritis Rheum. 1998 Sep;41(9):1613-9.

PMID:
9751093
[PubMed - indexed for MEDLINE]
3.

Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients.

Teixeira L, Mouthon L, Mahr A, Berezné A, Agard C, Mehrenberger M, Noël LH, Trolliet P, Frances C, Cabane J, Guillevin L; Group Français de Recherche sur le Sclérodermie (GFRS).

Ann Rheum Dis. 2008 Jan;67(1):110-6. Epub 2007 Jun 8.

PMID:
17557890
[PubMed - indexed for MEDLINE]
4.

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.

Arthritis Rheum. 2002 Nov;46(11):2983-9.

PMID:
12428241
[PubMed - indexed for MEDLINE]
Free Article
5.

The scleroderma kidney: progress in risk factors, therapy, and prevention.

Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L.

Curr Rheumatol Rep. 2011 Feb;13(1):37-43. doi: 10.1007/s11926-010-0145-7. Review.

PMID:
21061100
[PubMed - indexed for MEDLINE]
6.

Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.

Omae K, Ogawa T, Nitta K.

Heart Vessels. 2009 Jul;24(4):301-7. doi: 10.1007/s00380-008-1125-y. Epub 2009 Jul 22. Erratum in: Heart Vessels. 2009 Sep;24(5):391.

PMID:
19626404
[PubMed - indexed for MEDLINE]
7.

[Scleroderma renal crisis].

Teixeira L, Servettaz A, Mehrenberger M, Noël LH, Guillevin L, Mouthon L.

Presse Med. 2006 Dec;35(12 Pt 2):1966-74. Review. French.

PMID:
17159723
[PubMed - indexed for MEDLINE]
8.

Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls.

Guillevin L, Bérezné A, Seror R, Teixeira L, Pourrat J, Mahr A, Hachulla E, Agard C, Cabane J, Vanhille P, Harle JR, Deleveaux I, Mouthon L.

Rheumatology (Oxford). 2012 Mar;51(3):460-7. doi: 10.1093/rheumatology/ker271. Epub 2011 Nov 15.

PMID:
22087012
[PubMed - indexed for MEDLINE]
Free Article
9.

Serologic profile and mortality rates of scleroderma renal crisis in Italy.

Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G, Ruffatti A, Ferri C, Giacomelli R, Matucci-Cerinic M, Valentini G, Montecucco C.

J Rheumatol. 2009 Jul;36(7):1464-9. doi: 10.3899/jrheum.080806. Epub 2009 Jun 1.

PMID:
19487262
[PubMed - indexed for MEDLINE]
10.

Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor.

Hesselstrand R, Scheja A, Wuttge DM.

Scand J Rheumatol. 2012 Feb;41(1):39-43. doi: 10.3109/03009742.2011.610032. Epub 2011 Nov 1.

PMID:
22044051
[PubMed - indexed for MEDLINE]
11.

Renal complications and scleroderma renal crisis.

Denton CP, Lapadula G, Mouthon L, Müller-Ladner U.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii32-5. doi: 10.1093/rheumatology/ken483. Review.

PMID:
19487221
[PubMed - indexed for MEDLINE]
Free Article
12.

A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.

Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, Mahamid H, Bambara LM, Biasi D.

Clin Rheumatol. 2009 Jul;28(7):807-13. doi: 10.1007/s10067-009-1155-6. Epub 2009 Mar 20.

PMID:
19301062
[PubMed - indexed for MEDLINE]
13.

Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Trang G, Steele R, Baron M, Hudson M.

Rheumatol Int. 2012 Mar;32(3):645-53. doi: 10.1007/s00296-010-1697-6. Epub 2010 Dec 4. Review.

PMID:
21132302
[PubMed - indexed for MEDLINE]
14.

Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.

Yamada H, Suga N, Maeda K, Kimura Y, Miura N, Futenma A, Imai H.

Arzneimittelforschung. 2010;60(2):64-70. doi: 10.1055/s-0031-1296250.

PMID:
20329653
[PubMed - indexed for MEDLINE]
15.

Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R.

Clin Rheumatol. 2002 Jun;21(3):244-50.

PMID:
12111631
[PubMed - indexed for MEDLINE]
16.

Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Mouthon L, Bérezné A, Bussone G, Noël LH, Villiger PM, Guillevin L.

Clin Rev Allergy Immunol. 2011 Apr;40(2):84-91. doi: 10.1007/s12016-009-8191-5. Review.

PMID:
20012923
[PubMed - indexed for MEDLINE]
17.

Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.

Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG).

Semin Arthritis Rheum. 2012 Aug;42(1):42-55. doi: 10.1016/j.semarthrit.2012.01.003. Epub 2012 Mar 29.

PMID:
22464314
[PubMed - indexed for MEDLINE]
18.

Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment.

Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, Cleland L, Roberts-Thomson PJ.

Intern Med J. 2003 May-Jun;33(5-6):216-20.

PMID:
12752889
[PubMed - indexed for MEDLINE]
19.

Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.

Caramaschi P, Dalla Gassa A, Prati D, Barausse G, Tinazzi I, Ravagnani V, Confente S, Biasi D.

Rheumatol Int. 2012 Jul;32(7):1933-8. doi: 10.1007/s00296-011-1878-y. Epub 2011 Mar 30.

PMID:
21448643
[PubMed - indexed for MEDLINE]
20.

Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.

Airò P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):722-7.

PMID:
18078620
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk